Sessa Concetto, Castellino Pietro, Battaglia Giovanni G, Fatuzzo Pasquale, Gaudio Agostino, Granata Antonio, Lentini Paolo, Marcantoni Carmelita, Morale Walter, Musso Salvatore, Rapisarda Francesco, Santoro Domenico, Zanoli Luca
U.O.C. Nefrologia e Dialisi, P.O. "Maggiore" di Modica, Ragusa (RG), Italy.
Medicina Interna, Dipartimento di Medicina Clinica e Sperimentale, Università di Catania, Catania (CT), Italy.
G Ital Nefrol. 2020 Dec 7;37(6):2020-vol6.
Chronic kidney disease is associated with an increased cardiovascular risk. Several uremic toxins are also vascular toxins and may contribute to the increase of the cardiovascular risk through the development of aortic stiffening. In this process, oxidative stress and endothelial dysfunction play an important role. Considering that aortic stiffness is a known cardiovascular risk factor and a vascular biomarker involved in the development of chronic cardiac dysfunction, and that the reduction of aortic stiffness is associated with an improved survival of patients with end-stage kidney disease, we aim at reviewing the therapeutic options to reduce aortic stiffness and potentially the cardiovascular risk.
慢性肾脏病与心血管风险增加相关。几种尿毒症毒素也是血管毒素，可能通过主动脉硬化的发展导致心血管风险增加。在这个过程中，氧化应激和内皮功能障碍起着重要作用。鉴于主动脉僵硬是一个已知的心血管风险因素，也是参与慢性心脏功能障碍发展的血管生物标志物，并且主动脉僵硬的减轻与终末期肾病患者生存率的提高相关，我们旨在综述降低主动脉僵硬以及潜在降低心血管风险的治疗选择。
